预约演示
更新于：2025-02-17
Gadopentetate Dimeglumine
钆喷酸葡胺
更新于：2025-02-17
概要
基本信息
原研机构 |
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1988-06-02), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H36GdN4O15 |
InChIKeyLZQIEMULHFPUQY-BMWGJIJESA-J |
CAS号86050-77-3 |
关联
34
项与 钆喷酸葡胺 相关的临床试验NCT04776187
Safety Evaluation of Linear and Macrocyclic Gadolinium-Based Contrast Agents for Patients With Mild to Moderate Renal Insufficiency Undergoing Enhanced Magnetic Resonance Imaging (Interventional Prospective Study) Clinical Trial Protocol
NCT02371798
Diagnosing Endolymphatic Hydrops in Patients With Meniere Disease Using Magnetic Resonance Imaging With Intravenous Gadolinium Administration
NCT02278510
A Pilot Trial of Intraparenchymally-Administered Topotecan Using Convection-Enhanced Delivery (CED) in Patients With Suspected Recurrent/Progressive WHO Grade III or IV (High Grade) Glioma Requiring Stereotactic Biopsy
100 项与 钆喷酸葡胺 相关的临床结果
登录后查看更多信息
100 项与 钆喷酸葡胺 相关的转化医学
登录后查看更多信息
100 项与 钆喷酸葡胺 相关的专利（医药）
登录后查看更多信息
5,937
项与 钆喷酸葡胺 相关的文献（医药）2025-02-01CLINICAL RADIOLOGY
Comparative study of 3D-T2WI vs. 3D-T2-FLAIR MRI in displaying human meningeal lymphatics vessels
Article
作者: Fang, Y ; Lai, Tianmin ; Zhao, Y ; Lin, Y ; Zhao, Yihan ; Fu, Ying ; Song, X ; Lai, T. ; Sun, Y. ; Fang, Yaofeng ; Sun, Yuyu ; Bao, Q. ; Hu, Tao ; Zhao, Y. ; Bao, Quan ; Song, Xin ; Hu, T ; Fang, Y. ; Lin, Y. ; Song, X. ; Sun, Y ; Hu, T. ; Bao, Q ; Lin, Yi ; Lai, T
AIM:
Various magnetic resonance imaging (MRI) sequences can be utilized to visualize human meningeal lymphatic vessels (MLVs) for investigating the associations between MLVs and central nervous system (CNS) disorders. This study aimed to compare the quality of contrast-enhanced 3D-T2WI and 3D-T2-fluid-attenuated inversion recovery (FLAIR) MRI sequences to display human MLVs.
MATERIALS AND METHODS:
Sixty-two patients (27 males, 35 females; mean age 55.8 ± 14.9 years) underwent 3D-T2WI and 3D-T2-FLAIR scan in combination with Gd-DTPA injection to show MLVs.
RESULTS:
(1) The positivity rates of the 3D-T2WI sequence were 98.4%, 29.0%, and 46.8%, around the dural sinus, middle meningeal artery, and ethmoid sinus, respectively. The positivity rates of the 3D-T2-FLAIR sequence were 100%, 48.4%, and 66.1%, respectively. The positivity rate was significantly higher with the 3D-T2-FLAIR sequence compared with the 3D-T2WI sequence for the middle meningeal artery and ethmoid sinus regions (p < 0.05). (2) In patients with brain lesions and intracranial space-occupying lesions, the positivity rate was significantly higher with the 3D-T2-FLAIR sequence compared with the 3D-T2WI sequence for the middle meningeal artery and ethmoid sinus regions (p < 0.05). (3) The mean cross-sectional areas of MLVs around the dural sinus, middle meningeal artery, and ethmoid sinus were all higher using the 3D-T2-FLAIR sequence compared with the 3D-T2WI sequence at all three sites (p < 0.01). (4) The signal intensity was significantly higher using the 3D-T2-FLAIR sequence compared with the 3D-T2WI sequence around the dural sinus and ethmoid sinus (p < 0.001).
CONCLUSION:
The 3D-T2-FLAIR sequence contrast-enhanced scan showed superior visualization of MLVs compared with the 3D-T2WI sequence.
2025-01-29ACS Applied Materials & Interfaces
Electrochemical Filtration of Gadolinium from Patient Urine after Magnetic Resonance Imaging
Article
作者: Wijesinghe, Sethma ; Allen, Matthew J. ; Kovaci, Christa ; Wang, Bingwen ; Luo, Long ; Ranaweera, Ruchiranga ; Weerarathna, Udeshika
The widespread use of gadolinium-based contrast agents for magnetic resonance imaging (MRI) in recent decades has led to a growing demand for Gd and raised environmental concerns due to their direct discharge into wastewater systems. In response, we developed an electrochemical filtration method to recover Gd from patient urine following contrast-enhanced MRI. This method involves modifying a conventional vacuum filtration apparatus by introducing electrodes into the filter membrane, creating a strong electric field of ∼5 kV/m and a steep three-zone pH gradient within the filter membrane. These electric and pH fields facilitate the dissociation of Gd-based contrast agents, releasing GdIII ions, electrophoretic separation of GdIII and its ligand, and eventually precipitation and trapping of GdIII as GdPO4 and Gd(OH)3 on the filter membrane. Using gadopentetate dimeglumine (GdDTPA) as a model Gd-based contrast agent, we achieved a Gd trapping efficiency of ∼70% for artificial and real urine samples. For macrocyclic Gd-based contrast agents such as gadoterate meglumine (GdDOTA), the Gd trapping efficiency decreased to 25.4% due to the slow dissociation kinetics of macrocyclic contrast agents. However, the trapping efficiency can be improved to ∼40% by allowing the macrocyclic contrast agent to predissociate in an acidic environment before electrochemical filtration. The Gd trapped on the filter membrane can be recovered by thermal treatment in a muffle furnace. After thermal treatment, the reclaimed Gd from the real urine sample was primarily identified as GdPO4. This electrochemical filtration design offers a straightforward and practical approach to recovering Gd from contrast-enhanced MRI scans, addressing the increasing demand for Gd and helping alleviate concerns about Gd contamination in surface water.
2025-01-28ACS Nano
PEGylated Ultrasmall Iron Oxide Nanoparticles as MRI Contrast Agents for Vascular Imaging and Real-Time Monitoring
Article
作者: Xu, Keyang ; Cao, Xiaoyi ; Gao, Mingyuan ; Lu, Kuan ; Zeng, Jianfeng ; Zhang, Ruru ; Wang, Hongzhao ; Wang, Ning ; Li, Cang ; Yang, Zhe ; Cai, Wu
Accurate imaging evaluations of pre- and post-treatment of cardiovascular diseases are pivotal for effective clinical interventions and improved patient outcomes. However, current imaging methods lack real-time monitoring capabilities with a high contrast and resolution during treatments. This study introduces PEGylated ultrasmall iron oxide nanoparticles (PUSIONPs), which have undergone comprehensive safety evaluations, boasting an r1 value of 6.31 mM-1 s-1, for contrast-enhanced magnetic resonance angiography (MRA). Systematic comparisons against common clinical methods in rabbits reveal that PUSIONPs-enhanced MRA exhibited improved vascular contrast, clearer vascular boundaries, and superior vessel resolution. Moreover, owing to their nanosize, PUSIONPs demonstrate significantly prolonged blood circulation compared to small molecular contrast agents such as Magnevist and Ultravist. This extended circulation enables captivating real-time monitoring of thrombolysis treatment for up to 4 h in rabbit models postsingle contrast agent injection. Additionally, in larger animal models such as beagles and Bama minipigs, PUSIONPs-enhanced MRA also showcases superior contrast effects, boundary delineation, and microvessel visualization, underscoring their potential to transform cardiovascular imaging, particularly in real-time monitoring and high-resolution visualization during treatment processes.
100 项与 钆喷酸葡胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 造影剂 | 美国 | 1988-06-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 心血管畸形 | 临床3期 | - | 2003-12-01 | |
| 病理性缩窄 | 临床3期 | - | 2003-12-01 | |
| 肾动脉阻塞 | 临床3期 | - | 2003-12-01 | |
| 外周血管疾病 | 临床3期 | - | 2003-03-01 | |
| 脑转移瘤 | 临床3期 | 日本 | 2003-02-01 | |
| 心肌梗塞 | 临床2期 | 美国 | 2006-03-01 | |
| 心肌梗塞 | 临床2期 | 阿根廷 | 2006-03-01 | |
| 外周动脉疾病 | 临床2期 | 日本 | 2004-07-01 | |
| 血管动脉疾病 | 临床2期 | 日本 | 2004-07-01 | |
| 原发性免疫缺陷疾病 | 临床2期 | 美国 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 2 | 3 Tesla Magnetic Resonance Imaging+Magnevist® (Intravenous (IV) administration of MRI contrast agent) | 製網鏇遞遞窪簾鬱餘糧(鬱選製窪夢淵獵觸襯夢) = 淵壓憲夢範製齋蓋齋蓋 鬱簾衊窪鹹繭鏇築觸獵 (觸襯淵鏇鏇鑰鹹觸繭淵, 積構膚網憲願繭顧網築 ~ 齋壓鬱窪衊糧蓋製糧醖) 更多 | - | 2018-07-11 | ||
N/A | 17 | 繭壓齋壓願網襯壓積顧(願壓蓋鹹鏇製膚顧選夢) = 願窪鏇鬱顧願夢夢製鏇 壓艱夢廠憲襯廠築繭夢 (顧願夢積鏇鹽積餘鬱構, 窪廠網範選膚鬱範襯餘 ~ 襯鹽淵鹽製蓋觸齋積醖) 更多 | - | 2017-06-14 | |||
N/A | 6 | 鬱製構齋鑰網顧觸積憲(鏇獵夢鏇鹽膚鹽襯艱築) = 淵廠繭醖鏇醖鏇淵積淵 鏇積壓糧醖築醖鏇膚淵 (遞壓鬱願襯觸選糧夢願, 選遞窪簾壓範製廠艱鏇 ~ 製遞構夢夢積醖膚網願) 更多 | - | 2016-02-12 | |||
N/A | - | IV contrast media (Gadopentetate Dimeglumine) | 遞繭觸廠獵壓觸顧鬱淵(餘糧艱醖積鑰鬱餘糧簾) = This is a rare case of grand mal seizures that occurred in a patient without any previous seizure history and not immediately after the injection of the contrast media, as it was till now reported in the literature. 衊蓋鹹襯鬱製夢餘遞繭 (鬱構餘壓構襯憲鑰鏇襯 ) | - | 2013-06-26 | ||
临床3期 | - | 46 | 範鹹餘廠壓鹹網顧糧鏇(夢鹽艱鏇淵願襯憲繭廠) = 顧築遞積夢齋鏇範襯醖 鹹艱觸壓範願願艱夢壓 (獵獵繭夢顧餘構簾衊觸 ) 更多 | 积极 | 2013-04-01 | ||
範鹹餘廠壓鹹網顧糧鏇(夢鹽艱鏇淵願襯憲繭廠) = 餘壓齋膚鏇膚網鬱鑰夢 鹹艱觸壓範願願艱夢壓 (獵獵繭夢顧餘構簾衊觸 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用